Journal article
GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS
Abstract
Abstract
BTFC travel award recipient
Glioblastoma (GBM) is a lethal brain tumor. Despite intensive standard of care (SoC) consisting of surgical resection followed by radiation therapy (RT) and chemotherapy with temozolomide (TMZ), tumor relapse is inevitable with a median overall survival of 14.6 months. Therapeutic failure is attributable to the presence of GBM stem-like cells (GSCs), which are highly resistant to genotoxic therapies, …
Authors
Brakel B; Saleh A; Saleh M; Miletic P; Salim S; Maich W; Brown KR; Tieu D; Venugopal C; Moffat J
Journal
Neuro-Oncology Advances, Vol. 5, No. Suppl 2, pp. i1–i2
Publisher
Oxford University Press (OUP)
Publication Date
July 12, 2023
DOI
10.1093/noajnl/vdad071.004
ISSN
0801-3284